SERB receives EU approval for Voraxaze® (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity
14. Januar 2022 11:10 ET
|
BTG Specialty Pharmaceuticals
London, Jan. 14, 2022 (GLOBE NEWSWIRE) -- SERB and BTG Specialty Pharmaceuticals today announced that the European Commission has granted marketing authorisation for Voraxaze® (glucarpidase) to...
Se presenta la primera evidencia de toxicidad relacionada con el metotrexato en dosis elevadas en España durante la Virtual ISPOR Europe 2021
02. Dezember 2021 03:45 ET
|
BTG Specialty Pharmaceuticals
COPENHAGUE, Dinamarca, Dec. 02, 2021 (GLOBE NEWSWIRE) -- La primera evidencia de la toxicidad relacionada con el metotrexato en dosis elevadas (HDMTX) en España se expuso hoy en la Virtual ISPOR...
First Evidence of High-Dose Methotrexate Related Toxicity in Spain Presented at Virtual ISPOR Europe 2021
01. Dezember 2021 02:00 ET
|
BTG Specialty Pharmaceuticals
COPENHAGEN, Denmark, Dec. 01, 2021 (GLOBE NEWSWIRE) -- The first evidence of high dose methotrexate related toxicity (HDMTX) in Spain was presented today at Virtual ISPOR Europe 2021, a global...
BTG Specialty Pharmaceuticals Calls on Consumers and Retailers to Consider the Facts About Venom Extractors
20. April 2021 11:58 ET
|
BTG Specialty Pharmaceuticals
WEST CONSHOHOCKEN, Pa., April 20, 2021 (GLOBE NEWSWIRE) -- To prepare for snakebite season, BTG Specialty Pharmaceuticals, a maker of critical care medicines, calls on outdoor enthusiasts to throw...